CHMP Issues Positive Opinion for Tablet Formulation of Merck's NOXAFIL

Merck , known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency recipients with graft-versus-host disease or those with hematologic malignancies with prolonged neutropenia from chemotherapy.

http://ift.tt/1cgjry7